Insulin therapy in type 2 diabetes: Role of the long-acting insulin glargine analogue

European Journal of Clinical Investigation

Volumn 34, Issue 6, 2004, Pages 410-416

  Yki Jarvinen H ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Division of Diabetes   (Finland)

Author keywords

Hypoglycaemia; Liver fat; Treatment

Indexed keywords

GLIMEPIRIDE; HUMAN INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA;

ACIDITY; ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TITRIMETRY;

DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RANDOMIZED CONTROLLED TRIALS;

EID: 3042711828     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01356.x     Document Type: Article

References (43)

1. Peters AL, Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med 1991;115:45-53.
2. Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? Diabetes Care 1992;15:953-9.
3. Yki-Järvinen H. Comparison of insulin regimens for patients with type 2 diabetes. Curr Opin Endocrinol Diab 2000;7:175-83.
4. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-67.
5. Yki-Järvinen H. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Merab Res 2002;18 (Suppl. 3):S77-S81.
6. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6.
7. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426-33.
8. Landstedt-Hallin L, Adamson U, Arner P, Bolinder J, Lins P-E. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995;18:1183-6.
9. Bastyr EJ, Johnson ME, Trautmann ME, Anderson JHJ, Vignati L. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 1999;21:1703-14.
10. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:182-8.
11. Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999;130:389-96.
12. Sindelka G, Heinemann L, Berger M, Frenck W, Chantelau E. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 1994;37:377-80.
13. Kolendorf K, Bojsen J, Deckert T. Clinical factors influencing the absorption of 125I-NPH insulin in diabetic patients. Horm Metab Res 1983;15:274-8.
14. Vora JP, Burch A, Peters JR, Owens DR. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care 1992;15:1484-93.
15. Ryysy L, Häkkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749-58.
16. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151-67.
17. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, DiVincenzo A et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8.
18. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9.
19. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000;23:813-9.
20. Heise T, Bott S, Rave K, Dressler A, Rosskamp R, Heinemann L. No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. Diabet Med 2002;19:490-5.
21. Mudaliar S, Mohideen P, Deutsch R, Ciaraldi T-P, Armstrong D, Kim B et al. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care 2002;25:1597-602.
22. Dagogo-Jack S, Askari H, Morrill B, Lehner LL, Kim B, Sha X. Physiological responses during hypoglycaemia induced by regular human insulin or a novel human analogue, insulin glargine. Diabetes Obes Metab 2000;2:373-83.
23. Westerbacka J, Bergholm R, Tiikkainen M, Yki-Jarvinen H. Glargine and regular human insulin similarly acutely enhance endothelium-dependent vasodilatation in normal subjects. Arterioscler Thromb Vasc Biol 2004;24:320-4.
24. Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2000;20:545-50.
25. Yki-Järvinen H, Nikkilä E, Helve E, Taskinen M-R. Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. Am J Med 1988;84:185-92.
26. Tamminen M, Westerbacka J, Vehkavaara S, Yki-Jarvinen H. Insulin-induced decreases in aortic wave reflection and central systolic pressure are impaired in type 2 diabetes. Diabetes Care 2002;25:2314-9.
27. Vehkavaara S, Yki-Jarvinen H. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2004;24:325-30.
28. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005.
29. Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry RR. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells. Comparisons to insulin and IGF-I. J Clin Endocrinol Metab 2001;86:5838-47.
30. Bahr M, Kolter T, Seipke G, Eckel J. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997;320:259-65.
31. Chisalita SI, Arnqvist HJ. Insulin-like growth factor-I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells. Am J Physiol Endocrinol Metab 2004;286:E896-901.
32. Dideriksen LH, Jorgensen LN, Drejer K. Carcinogenic effect on female rats after 12 months administration of the insulin analogue B (10) Asp. Diabetes 2004;41 (Suppl. 1):143A (Abstract).
33. Berti L, Bossenmeijer M, Kellerer E, Seffer G, Seipke G, Häring H. Comparison of the human insulin analogs HOE 901 and Asp (B10): characteristics of receptor binding, activation and tyrosine phosphorylation of different substrate proteins. Diabetologia 1995;38 (Suppl. 1):A191 (Abstract).
34. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group [In Process Citation]. Diabetes Care 2000;23:1130-6.
35. Rosenstock J, Schwartz SL, Clark CMJ, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes. 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6.
36. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
37. Riddle MC, Rosenstock J, Gerich J. On behalf of the insulin glargine 4002 study investigators: the Treat-to-Target Trial. Diabetes Care 2003;26:3080-6.
38. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijärvi A et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023-8.
39. Tiikkainen M, Tamminen M, Hakkinen AM, Bergholm R, Vehkavaara S, Halavaara J et al. Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. Obes Res 2002;10:859-67.
40. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
41. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
42. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952-9.
43. Cryer P. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999;15:42-6. (Abstract).